On the basis of the O.O. Bogomolets National Medical University, under the leadership of professor, head of the department of urology, doctor of medical sciences Nikitin O.D., a long-term study of the drug VOGER was completed.

VOGER is a unique drug that we created in 2020. VOGER includes all the components listed in the "Phytotherapy" section of the 2019 European Association of Urologists Recommendations for the treatment of benign prostatic hyperplasia in men.

So, the obtained data indicate a 96.8% therapeutic efficiency of the drug VOGER, and when evaluating the side effects, it turned out that most of them had a mild degree of severity and disappeared during the treatment without any correction.


According to the results, VOGER for 6 months in prostatitis and BPH showed:

  1. 43% reduction in perineal pain
  2. reduction of pain in the lumbosacral area by 46%
  3. reduction of pain in the groin area by 18%
  4. dysuric phenomena disappeared in 69% of men
  5. asthenic syndrome disappeared in 71%
  6. general weakness disappeared in 60%
  7. mood deterioration decreased by 41%
  8. and irritability decreased in 45.5% of patients
  9. the value of the average volume of urination increased from 12.2 to 16.


In patients with adenoma, VOGER showed

  1. decrease in the number of points on the IPSS scale (interruption and weakening of the stream of urine, the feeling of incomplete emptying of the bladder, pollakiuria, imperative urges) from 24 to 5 points
  2. the maximum rate of urination in the main BPH group probably increased from 6.2 to 18.1
  3. the average frequency of nocturnal urination decreased from 3.6 to 1.9
  4. and the average frequency of daytime urination — from 6.2 to 4.8


Congratulations to the BICHELS team on their achievement! Helping even more people to improve their health!